Biocon Gains India Approval for Liraglutide

  Published 10 months ago

Biocon Pharma received CDSCO approval for its generic Liraglutide, a drug for type 2 diabetes, using the streamlined '101 route'. This initiative aims to increase access to affordable diabetes treatment in India, where the disease has a high prevalence.

  • Generic version of Victoza approved in India.
  • Approval via CDSCO’s ‘101 route’ for faster access.
  • Addresses the growing diabetes epidemic in India.

You might like these

India Eases Bank Ownership Rules for Foreign Investors

NTPC Expands Capacity with New 660 MW Unit

Netflix: Live Events & Analyst Downgrade

Lupin & Zentiva Partner on Biosimilar

India Inflation Outlook & Rate Cuts

DLPL Boosts Genomics with NovaSeq X Expansion

Policybazaar Fined ₹5 Crore by Regulator

News that matters the most ⚡